Patients with overactive bladder (OAB) treated with VESIcare(R) (solifenacin succinate) experienced statistically significant reductions in episodes of urgency (the sudden, compelling need to urinate), according to a new study presented today at the 36th Annual Meeting of the International Continence Society.

A secondary endpoint from this study also presented today demonstrated that patients taking VESIcare experienced a statistically significant increase in warning time -- compared with patients taking placebo (31.5 seconds vs. 12.0 seconds median increase, respectively; p

Tag Cloud